New York Angels

New York Angels is one of the longest-running angel networks in the United States, and the New York ecosystem density it draws on is the central feature of the proposition. The network invests at pre-seed and seed across a broad set of categories, with healthcare technology and digital health a consistent area of activity and an explicit AI focus. For founders, the value is the access to a wide and operationally varied membership rather than a single decision-maker’s capital.

The thesis at the network level is digital health and healthcare software, with a working preference for companies whose products navigate the regulatory environment thoughtfully and whose unit economics are credible at the seed stage. AI focus is real and reflects the broader direction of healthcare technology, though the network is comfortable with non-AI software companies provided the underlying business is sound. Founders pursuing pure pharma or device-only plays where the regulatory horizon is long are typically a less natural fit for an angel network than for a specialist fund.

Checks fall in the two hundred and fifty thousand to one million dollar range, syndicated across the membership rather than written by a single decision-maker. The structure means that founders engage with the network’s leadership, then with interested members, and ultimately receive an aggregation of individual angel commitments. Geography is anchored in the New York ecosystem, with engagement extending to companies with a credible reason to operate in or around the region.

The network is a member organization rather than a fund, with a leadership team that runs the process and a broad membership that commits the capital. That structure shapes both the engagement and the operational support a founder eventually receives.

The approach is process-driven by angel-network standards, with an explicit pitch and diligence phase before the syndication closes. The leverage is the depth and breadth of the membership: operators, executives, and former founders whose individual checks come with relevant network and operating experience. Founders should expect a structured engagement rather than a single conversation, and should plan timelines accordingly. Follow-on participation in subsequent rounds is common when companies progress on plan, and the network’s relationships with New York institutional investors can shorten the path to a Series A. For healthcare technology founders building in or around New York and looking for a syndicated angel base with operating depth, the fit is direct; founders looking for a single decisive check should approach a fund instead.